http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 05 Mar 2026 18:30:00 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Zura+Bio+Ltd++++++++++++++For%3A+Feb+21++Filed+by%3A+Nirula+Ajay/26120770.html si-local-file:///var/storage/secattach/20260305/26120770.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Zura+Bio+Ltd++++++++++++++For%3A+Feb+21++Filed+by%3A+Nirula+Ajay/26120770.html Thu, 05 Mar 2026 18:30:00 +0000 O.50982924 ZURA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Zura+Bio+Ltd++++++++++++++For%3A+Feb+21++Filed+by%3A+Nirula+Ajay/26120770.html si-local-file:///var/storage/secattach/20260305/26120770.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Zura+Bio+Ltd++++++++++++++For%3A+Feb+21++Filed+by%3A+Nirula+Ajay/26120770.html Thu, 05 Mar 2026 18:30:00 +0000 O.50982924 ZURA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Zura+Bio+Ltd++++++++++++++For%3A+Feb+21++Filed+by%3A+Nirula+Ajay/26120765.html si-local-file:///var/storage/secattach/20260305/26120765.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Zura+Bio+Ltd++++++++++++++For%3A+Feb+21++Filed+by%3A+Nirula+Ajay/26120765.html Thu, 05 Mar 2026 18:29:00 +0000 O.50982924 ZURA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Zura+Bio+Ltd++++++++++++++For%3A+Feb+21++Filed+by%3A+Nirula+Ajay/26120765.html si-local-file:///var/storage/secattach/20260305/26120765.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Zura+Bio+Ltd++++++++++++++For%3A+Feb+21++Filed+by%3A+Nirula+Ajay/26120765.html Thu, 05 Mar 2026 18:29:00 +0000 O.50982924 ZURA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Zura+Bio+Ltd++++++++++++++For%3A+Mar+05/26114932.html si-local-file:///var/storage/secattach/20260305/26114932.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Zura+Bio+Ltd++++++++++++++For%3A+Mar+05/26114932.html Thu, 05 Mar 2026 07:01:00 +0000 O.50982924 ZURA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Zura+Bio+Ltd++++++++++++++For%3A+Mar+05/26114932.html si-local-file:///var/storage/secattach/20260305/26114932.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Zura+Bio+Ltd++++++++++++++For%3A+Mar+05/26114932.html Thu, 05 Mar 2026 07:01:00 +0000 O.50982924 ZURA http://www.streetinsider.com/FDA/Zura+Bio+to+present+Phase+2+systemic+sclerosis+trial+design+at+congress/26114685.html <p>Zura Bio Limited (NASDAQ: ZURA) announced that its Phase 2 TibuSURE clinical trial design has been accepted for poster presentation at the 9th Systemic Sclerosis World Congress, scheduled for March 5-7, 2026 in Athens, Greece.</p> <p>The poster will outline the rationale and design of the global Phase 2 study evaluating tibulizumab (ZB-106) in systemic sclerosis patients. No clinical efficacy or safety data will be presented, according to the company's statement.</p> <p>TibuSURE represents the first clinical trial designed to evaluate dual inhibition of interleukin-17A and B-cell activating factor in diffuse cutaneous systemic sclerosis. Tibulizumab is an investigational bispecific antibody engineered to simultaneously neutralize http://www.streetinsider.com/FDA/Zura+Bio+to+present+Phase+2+systemic+sclerosis+trial+design+at+congress/26114685.html Thu, 05 Mar 2026 06:30:45 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/FDA/Zura+Bio+to+present+Phase+2+systemic+sclerosis+trial+design+at+congress/26114685.html <p>Zura Bio Limited (NASDAQ: ZURA) announced that its Phase 2 TibuSURE clinical trial design has been accepted for poster presentation at the 9th Systemic Sclerosis World Congress, scheduled for March 5-7, 2026 in Athens, Greece.</p> <p>The poster will outline the rationale and design of the global Phase 2 study evaluating tibulizumab (ZB-106) in systemic sclerosis patients. No clinical efficacy or safety data will be presented, according to the company's statement.</p> <p>TibuSURE represents the first clinical trial designed to evaluate dual inhibition of interleukin-17A and B-cell activating factor in diffuse cutaneous systemic sclerosis. Tibulizumab is an investigational bispecific antibody engineered to simultaneously neutralize http://www.streetinsider.com/FDA/Zura+Bio+to+present+Phase+2+systemic+sclerosis+trial+design+at+congress/26114685.html Thu, 05 Mar 2026 06:30:45 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/FDA/Zura+Bio+to+present+Phase+2+systemic+sclerosis+trial+design+at+congress/26114685.html <p>Zura Bio Limited (NASDAQ: ZURA) announced that its Phase 2 TibuSURE clinical trial design has been accepted for poster presentation at the 9th Systemic Sclerosis World Congress, scheduled for March 5-7, 2026 in Athens, Greece.</p> <p>The poster will outline the rationale and design of the global Phase 2 study evaluating tibulizumab (ZB-106) in systemic sclerosis patients. No clinical efficacy or safety data will be presented, according to the company's statement.</p> <p>TibuSURE represents the first clinical trial designed to evaluate dual inhibition of interleukin-17A and B-cell activating factor in diffuse cutaneous systemic sclerosis. Tibulizumab is an investigational bispecific antibody engineered to simultaneously neutralize http://www.streetinsider.com/FDA/Zura+Bio+to+present+Phase+2+systemic+sclerosis+trial+design+at+congress/26114685.html Thu, 05 Mar 2026 06:30:45 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/FDA/Zura+Bio+to+present+Phase+2+systemic+sclerosis+trial+design+at+congress/26114685.html <p>Zura Bio Limited (NASDAQ: ZURA) announced that its Phase 2 TibuSURE clinical trial design has been accepted for poster presentation at the 9th Systemic Sclerosis World Congress, scheduled for March 5-7, 2026 in Athens, Greece.</p> <p>The poster will outline the rationale and design of the global Phase 2 study evaluating tibulizumab (ZB-106) in systemic sclerosis patients. No clinical efficacy or safety data will be presented, according to the company's statement.</p> <p>TibuSURE represents the first clinical trial designed to evaluate dual inhibition of interleukin-17A and B-cell activating factor in diffuse cutaneous systemic sclerosis. Tibulizumab is an investigational bispecific antibody engineered to simultaneously neutralize http://www.streetinsider.com/FDA/Zura+Bio+to+present+Phase+2+systemic+sclerosis+trial+design+at+congress/26114685.html Thu, 05 Mar 2026 06:30:45 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/FDA/Zura+Bio+to+present+Phase+2+systemic+sclerosis+trial+design+at+congress/26114685.html <p>Zura Bio Limited (NASDAQ: ZURA) announced that its Phase 2 TibuSURE clinical trial design has been accepted for poster presentation at the 9th Systemic Sclerosis World Congress, scheduled for March 5-7, 2026 in Athens, Greece.</p> <p>The poster will outline the rationale and design of the global Phase 2 study evaluating tibulizumab (ZB-106) in systemic sclerosis patients. No clinical efficacy or safety data will be presented, according to the company's statement.</p> <p>TibuSURE represents the first clinical trial designed to evaluate dual inhibition of interleukin-17A and B-cell activating factor in diffuse cutaneous systemic sclerosis. Tibulizumab is an investigational bispecific antibody engineered to simultaneously neutralize http://www.streetinsider.com/FDA/Zura+Bio+to+present+Phase+2+systemic+sclerosis+trial+design+at+congress/26114685.html Thu, 05 Mar 2026 06:30:45 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/FDA/Zura+Bio+to+present+Phase+2+systemic+sclerosis+trial+design+at+congress/26114685.html <p>Zura Bio Limited (NASDAQ: ZURA) announced that its Phase 2 TibuSURE clinical trial design has been accepted for poster presentation at the 9th Systemic Sclerosis World Congress, scheduled for March 5-7, 2026 in Athens, Greece.</p> <p>The poster will outline the rationale and design of the global Phase 2 study evaluating tibulizumab (ZB-106) in systemic sclerosis patients. No clinical efficacy or safety data will be presented, according to the company's statement.</p> <p>TibuSURE represents the first clinical trial designed to evaluate dual inhibition of interleukin-17A and B-cell activating factor in diffuse cutaneous systemic sclerosis. Tibulizumab is an investigational bispecific antibody engineered to simultaneously neutralize http://www.streetinsider.com/FDA/Zura+Bio+to+present+Phase+2+systemic+sclerosis+trial+design+at+congress/26114685.html Thu, 05 Mar 2026 06:30:45 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/FDA/Zura+Bio+to+present+Phase+2+systemic+sclerosis+trial+design+at+congress/26114685.html <p>Zura Bio Limited (NASDAQ: ZURA) announced that its Phase 2 TibuSURE clinical trial design has been accepted for poster presentation at the 9th Systemic Sclerosis World Congress, scheduled for March 5-7, 2026 in Athens, Greece.</p> <p>The poster will outline the rationale and design of the global Phase 2 study evaluating tibulizumab (ZB-106) in systemic sclerosis patients. No clinical efficacy or safety data will be presented, according to the company's statement.</p> <p>TibuSURE represents the first clinical trial designed to evaluate dual inhibition of interleukin-17A and B-cell activating factor in diffuse cutaneous systemic sclerosis. Tibulizumab is an investigational bispecific antibody engineered to simultaneously neutralize http://www.streetinsider.com/FDA/Zura+Bio+to+present+Phase+2+systemic+sclerosis+trial+design+at+congress/26114685.html Thu, 05 Mar 2026 06:30:45 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/FDA/Zura+Bio+to+present+Phase+2+systemic+sclerosis+trial+design+at+congress/26114685.html <p>Zura Bio Limited (NASDAQ: ZURA) announced that its Phase 2 TibuSURE clinical trial design has been accepted for poster presentation at the 9th Systemic Sclerosis World Congress, scheduled for March 5-7, 2026 in Athens, Greece.</p> <p>The poster will outline the rationale and design of the global Phase 2 study evaluating tibulizumab (ZB-106) in systemic sclerosis patients. No clinical efficacy or safety data will be presented, according to the company's statement.</p> <p>TibuSURE represents the first clinical trial designed to evaluate dual inhibition of interleukin-17A and B-cell activating factor in diffuse cutaneous systemic sclerosis. Tibulizumab is an investigational bispecific antibody engineered to simultaneously neutralize http://www.streetinsider.com/FDA/Zura+Bio+to+present+Phase+2+systemic+sclerosis+trial+design+at+congress/26114685.html Thu, 05 Mar 2026 06:30:45 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Press+Releases/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html <p> HENDERSON, Nev.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fzurabio.com%2F&amp;esheet=54439036&amp;newsitemid=20260305051263&amp;lan=en-US&amp;anchor=Zura+Bio+Limited&amp;index=1&amp;md5=84f873b4729fbd7753e6f2f531309f1b" shape="rect">Zura Bio Limited</a> (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the Systemic Sclerosis World Congress, taking place March 5–7, 2026 in Athens, Greece. </p><p> The poster, titled “<i>TibuSURE: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Efficacy, Safety, and http://www.streetinsider.com/Press+Releases/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html Thu, 05 Mar 2026 06:30:00 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Press+Releases/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html <p> HENDERSON, Nev.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fzurabio.com%2F&amp;esheet=54439036&amp;newsitemid=20260305051263&amp;lan=en-US&amp;anchor=Zura+Bio+Limited&amp;index=1&amp;md5=84f873b4729fbd7753e6f2f531309f1b" shape="rect">Zura Bio Limited</a> (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the Systemic Sclerosis World Congress, taking place March 5–7, 2026 in Athens, Greece. </p><p> The poster, titled “<i>TibuSURE: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Efficacy, Safety, and http://www.streetinsider.com/Press+Releases/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html Thu, 05 Mar 2026 06:30:00 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Press+Releases/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html <p> HENDERSON, Nev.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fzurabio.com%2F&amp;esheet=54439036&amp;newsitemid=20260305051263&amp;lan=en-US&amp;anchor=Zura+Bio+Limited&amp;index=1&amp;md5=84f873b4729fbd7753e6f2f531309f1b" shape="rect">Zura Bio Limited</a> (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the Systemic Sclerosis World Congress, taking place March 5–7, 2026 in Athens, Greece. </p><p> The poster, titled “<i>TibuSURE: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Efficacy, Safety, and http://www.streetinsider.com/Press+Releases/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html Thu, 05 Mar 2026 06:30:00 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Press+Releases/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html <p> HENDERSON, Nev.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fzurabio.com%2F&amp;esheet=54439036&amp;newsitemid=20260305051263&amp;lan=en-US&amp;anchor=Zura+Bio+Limited&amp;index=1&amp;md5=84f873b4729fbd7753e6f2f531309f1b" shape="rect">Zura Bio Limited</a> (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the Systemic Sclerosis World Congress, taking place March 5–7, 2026 in Athens, Greece. </p><p> The poster, titled “<i>TibuSURE: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Efficacy, Safety, and http://www.streetinsider.com/Press+Releases/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html Thu, 05 Mar 2026 06:30:00 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Press+Releases/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html <p> HENDERSON, Nev.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fzurabio.com%2F&amp;esheet=54439036&amp;newsitemid=20260305051263&amp;lan=en-US&amp;anchor=Zura+Bio+Limited&amp;index=1&amp;md5=84f873b4729fbd7753e6f2f531309f1b" shape="rect">Zura Bio Limited</a> (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the Systemic Sclerosis World Congress, taking place March 5–7, 2026 in Athens, Greece. </p><p> The poster, titled “<i>TibuSURE: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Efficacy, Safety, and http://www.streetinsider.com/Press+Releases/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html Thu, 05 Mar 2026 06:30:00 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Press+Releases/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html <p> HENDERSON, Nev.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fzurabio.com%2F&amp;esheet=54439036&amp;newsitemid=20260305051263&amp;lan=en-US&amp;anchor=Zura+Bio+Limited&amp;index=1&amp;md5=84f873b4729fbd7753e6f2f531309f1b" shape="rect">Zura Bio Limited</a> (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the Systemic Sclerosis World Congress, taking place March 5–7, 2026 in Athens, Greece. </p><p> The poster, titled “<i>TibuSURE: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Efficacy, Safety, and http://www.streetinsider.com/Press+Releases/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html Thu, 05 Mar 2026 06:30:00 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Press+Releases/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html <p> HENDERSON, Nev.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fzurabio.com%2F&amp;esheet=54439036&amp;newsitemid=20260305051263&amp;lan=en-US&amp;anchor=Zura+Bio+Limited&amp;index=1&amp;md5=84f873b4729fbd7753e6f2f531309f1b" shape="rect">Zura Bio Limited</a> (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the Systemic Sclerosis World Congress, taking place March 5–7, 2026 in Athens, Greece. </p><p> The poster, titled “<i>TibuSURE: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Efficacy, Safety, and http://www.streetinsider.com/Press+Releases/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html Thu, 05 Mar 2026 06:30:00 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Press+Releases/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html <p> HENDERSON, Nev.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fzurabio.com%2F&amp;esheet=54439036&amp;newsitemid=20260305051263&amp;lan=en-US&amp;anchor=Zura+Bio+Limited&amp;index=1&amp;md5=84f873b4729fbd7753e6f2f531309f1b" shape="rect">Zura Bio Limited</a> (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the Systemic Sclerosis World Congress, taking place March 5–7, 2026 in Athens, Greece. </p><p> The poster, titled “<i>TibuSURE: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Efficacy, Safety, and http://www.streetinsider.com/Press+Releases/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html Thu, 05 Mar 2026 06:30:00 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Business+Wire/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html <p> HENDERSON, Nev.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fzurabio.com%2F&amp;esheet=54439036&amp;newsitemid=20260305051263&amp;lan=en-US&amp;anchor=Zura+Bio+Limited&amp;index=1&amp;md5=84f873b4729fbd7753e6f2f531309f1b" shape="rect">Zura Bio Limited</a> (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the Systemic Sclerosis World Congress, taking place March 5–7, 2026 in Athens, Greece. </p><p> The poster, titled “<i>TibuSURE: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Efficacy, Safety, and http://www.streetinsider.com/Business+Wire/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html Thu, 05 Mar 2026 06:30:00 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Business+Wire/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html <p> HENDERSON, Nev.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fzurabio.com%2F&amp;esheet=54439036&amp;newsitemid=20260305051263&amp;lan=en-US&amp;anchor=Zura+Bio+Limited&amp;index=1&amp;md5=84f873b4729fbd7753e6f2f531309f1b" shape="rect">Zura Bio Limited</a> (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the Systemic Sclerosis World Congress, taking place March 5–7, 2026 in Athens, Greece. </p><p> The poster, titled “<i>TibuSURE: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Efficacy, Safety, and http://www.streetinsider.com/Business+Wire/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html Thu, 05 Mar 2026 06:30:00 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA http://www.streetinsider.com/Business+Wire/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html <p> HENDERSON, Nev.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fzurabio.com%2F&amp;esheet=54439036&amp;newsitemid=20260305051263&amp;lan=en-US&amp;anchor=Zura+Bio+Limited&amp;index=1&amp;md5=84f873b4729fbd7753e6f2f531309f1b" shape="rect">Zura Bio Limited</a> (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the Systemic Sclerosis World Congress, taking place March 5–7, 2026 in Athens, Greece. </p><p> The poster, titled “<i>TibuSURE: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Efficacy, Safety, and http://www.streetinsider.com/Business+Wire/Zura+Bio+to+Present+Phase+2+TibuSURE+Study+Design+Poster+Evaluating+Dual+IL-17A+and+BAFF+Inhibition+in+Systemic+Sclerosis+at+9th+Systemic+Sclerosis+World+Congress/26114676.html Thu, 05 Mar 2026 06:30:00 +0000 A.06822034 A.31293549 A.50216539 O.00573636 O.01981133 O.20026344 O.50982924 ZURA